40 results about "Fluvastatin Sodium" patented technology

The present invention provides an improved process for preparing HMG-CoA reductase inhibitors such as rosuvastatin calcium, fluvastatin sodium, and pitavastatin calcium under a mild condition, using a novel amide-bond-containing compound having R2-N-O-R1 moiety as a key intermediate. And also, the present invention provides the novel compound, an intermediate useful for the preparation thereof, and a process for the preparation thereof.

The present invention relates to novel anhydrous amorphous forms of bis[(E)[4-(4-fluorophenyl)isopropyl[methyl(methylsulfonyl)amino]pyrimidinyl](3R,5S)-3,5-dihydroxyhept enoic acid]calcium salt (rosuvastatin calcium), (±)7-(3-(4-fluorophenyl)-1-(1-methylethyl)-1H-indol-2-yl)3,5-dihydroxy heptenoic acid monosodium salt (fluvastatin sodium) and bis[(E)-3,5-dihydroxy-7-[4′-(4″-fluorophenyl)-2′-cyclopropyl-quinolin-3′-hept-6-enoic acid]calcium salt (pitavastatin calcium), to processes for their preparation, to pharmaceutical compositions containing them and to methods of treatment using the same. The rosuvastatin calcium, pitavastatin calcium and fluvastatin sodium obtained are known valuable agents useful in treating hyperlipidemia and hypercholestrolemia.

Provided are polymorphic forms of fluvastatin sodium and processes for their preparation.

The present invention is directed to a process for preparing Fluvastatin Sodium salt by basic hydrolysis of its alkyl ester. The reaction is performed in conditions suitable to allow a selective hydrolysis of the desired syn isomer, while the unwanted anti isomer is removed by extraction, thus reducing its content in the final product; this diastereomer is the main impurity of Fluvastatin sodium salt and its ester precursor.

Disclosed herein are novel polymorphic forms of Fluvastatin sodium, wherein said polymorphic forms are designated as JF, JF1, JF2, JF3 and are characterized by their powder X-ray diffraction patterns, Infrared absorption spectrums, thermo gravimetric analysis and differential scanning calorimetry. The processes for preparing said polymorphic forms are also disclosed. The present invention also relates to process for preparing amorphous form of Fluvastatin sodium.

The invention discloses a fluvastatin sodium compound and a preparation method thereof. The preparation method comprises the following steps of: 1, dissolving a fluvastatin sodium raw material in water, adding a proper amount of active carbon, stirring for adsorption, performing suction filtration, and collecting filtrate to obtain the primarily purified fluvastatin sodium-containing aqueous solution; 2, treating the aqueous solution by adding alkali metal or alkaline-earth metal alkoxides, and filtering to obtain filtrate, namely the secondarily purified fluvastatin sodium-containing aqueoussolution; and 3, adding a poor solvent of fluvastatin sodium into the solution, controlling temperature for recrystallization, centrifugally washing, and drying to obtain the triply purified fluvastatin sodium. By the method, the quality of the preparation product is improved, the toxic and side effects of the fluvastatin sodium in preparation of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors are reduced, and the method is particularly suitable for industrial production.

The invention provides a composite capable of preventing and controlling hyperlipidemia and heart vessel, cerebral vessel or neuron damage caused by the hyperlipidemia. The composite mainly comprises the following components in parts by mass: 10-40 parts of lycopene, 100 parts of vitamin C and 5-20 parts of fluvastatin sodium. The invention further provides a preparation method and a use method of the composite. The composite combines the low-dose lycopene, low-dose fluvastatin sodium and the certain-dose vitamin C for the first time based on an effect of the lycopene for efficiently preventing the hyperlipidemia from damaging a heart vessel, a cerebral vessel and a neuron and by virtue of an idea of system biology, so that synergetic effects of reducing blood fat, protecting the heart vessel, the cerebral vessel and the neuron and preventing non-infective chronic diseases are exerted; the dose of statins and the lycopene is reduced; toxic and side effects of a medicine are reduced; the cost of the medicine is lowered; and the composite has good economic and social benefits.

Provided is a process for preparing a polymorphic form of fluvastatin sodium, particularly Form XIV.

The invention relates the preparing method of non-shaped fluorine-vastatin sodium. The current technology has many defects. The method comprises the following steps: preparing menthol dissolution liquid, dissolving fluorine-vastatin calcium in the liquid, distilling and getting the menthol dissolution liquid which can be recovered. The invention has the advantages of simple technology and high productivity.